secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2026-07-29T21:06:38+00:00
Accession:  0001193125-26-324202
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology amends executive severance agreements for CEO, CCO, and COO
-------------------------------------------------------------------------

- CEO Wilson: 12 months base salary (non-CIC) or 24 months base + 200% bonus (CIC), full equity acceleration.
- CCO Powl and COO Ford: 12 months base (non-CIC) or 18 months base + 150% bonus (CIC), full equity acceleration.
- All executives get COBRA premium continuation (12 months non-CIC, 18-24 months CIC) and option exercise extension to 12 months.
- Amendments effective July 24-27, 2026; other terms unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526324202/0001193125-26-324202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526324202/d53075d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-324202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer